Evaxion Biotech A/S — Form 6-K Summary
Business Context and Reporting Period
Evaxion Biotech A/S, a Danish foreign private issuer, furnished this Form 6-K for February 2023. The report was signed and filed on February 6, 2023, by Bo Karmark, Chief Financial Officer.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Material Changes
The filing reports no financial or operating changes versus a prior comparable period. Its purpose is primarily procedural and relates to an upcoming extraordinary general meeting.
Guidance, Outlook, Risks, and Unusual Items
- An extraordinary general meeting was scheduled for February 21, 2023, at 5:00 p.m. CET.
- The filing includes the form of proxy for the extraordinary general meeting as Exhibit 99.1.
- The report is incorporated by reference into the company’s specified Form S-8, Form F-3, and Form F-1 registration statements, subject to subsequent filings.
- The filing text does not provide guidance, management outlook, risk updates, contingencies, or unusual financial items.
Key Facts to Verify
- Review Exhibit 99.1 for the matters submitted to shareholders and voting instructions.
- Confirm the outcome of the February 21, 2023 extraordinary general meeting in subsequent company filings.
- Obtain the company’s applicable annual or interim report for current financial metrics and liquidity information.